Macrogenics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 339
- Market Cap
- $215.1M
- Introduction
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
- Conditions
- Platinum-resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal CarcinomaClear Cell Adenocarcinoma of OvaryClear Cell Adenocarcinoma of VulvaClear Cell Adenocarcinoma of VaginaClear Cell Adenocarcinoma of CervixClear Cell Adenocarcinoma of UterusClear Cell Adenocarcinoma of Fallopian TubeClear Cell Adenocarcinoma of Peritoneum
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 60
- Registration Number
- NCT06730347
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸Ochsner MD Anderson Cancer Center, New Orleans, Louisiana, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
A Study of MGC028 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsNSCLC AdenocarcinomaCholangiocarcinomaPancreatic CarcinomaColorectal Carcinoma
- Interventions
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 124
- Registration Number
- NCT06723236
- Locations
- 🇺🇸
UCSF - Helen Diller Family Cancer Center, San Francisco, California, United States
🇺🇸Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States
🇺🇸South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan, United States
A Study of MGC026 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorAdvanced CancerMetastatic CancerSquamous Cell Carcinoma of Head and NeckNon Small Cell Lung CancerSmall-cell Lung CancerBladder CancerSarcomaEndometrial CancerMelanoma
- Interventions
- Biological: MGC026 Dose EscalationBiological: MGC026 Dose for Expansion
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 250
- Registration Number
- NCT06242470
- Locations
- 🇬🇧
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸START Midwest, Grand Rapids, Michigan, United States
A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Androgen-Independent Prostatic CancerAndrogen-Independent Prostatic NeoplasmsProstate Cancer RecurrentAndrogen-Insensitive Prostatic CanceAndrogen-Resistant Prostatic CancerHormone Refractory Prostatic CancerImmunotherapyImmune Checkpoint InhibitorInhibitory Checkpoint Molecule
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 154
- Registration Number
- NCT05848011
- Locations
- 🇺🇸
United Medical Group, Miami, Florida, United States
🇺🇸Orlando Health Cancer Institute, Orlando, Florida, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
- Conditions
- Non-small Cell Lung CancerAndrogen-Independent Prostatic CancerLaryngeal Squamous Cell CarcinomaMelanomaCastration-Resistant Prostatic CancerAndrogen-Insensitive Prostatic CancerHormone Refractory Prostatic CancerAnal CancerAnal NeoplasmHead and Neck Squamous Cell Carcinoma
- Interventions
- Biological: vobramitamab duocarmazine 2.0 mg (Arm A)Biological: vobramitamab duocarmazine 2.7 mg (Arm B)
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 382
- Registration Number
- NCT05551117
- Locations
- 🇪🇸
Institut Catala d'Oncologia Hospitalet, Barcelona, Spain
🇺🇸Compassionate Cancer Care Medical Group, Fountain Valley, California, United States
🇺🇸University of California Los Angeles (UCLA) Community Cancer Care, Los Angeles, California, United States
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
- Conditions
- Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin LymphomaLeukemia, B-cellLeukemia, Hairy CellMastocytosis, Aggressive SystemicBlastic Plasmacytoid Dendritic Cell NeoplasmChronic Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 90
- Registration Number
- NCT05362773
- Locations
- 🇺🇸
Colorado Blood Cancer Network, Denver, Colorado, United States
🇺🇸University of Maryland, Greenbaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
- Conditions
- Malignant MelanomaPancreatic Ductal CarcinomaRenal Cell CarcinomaAdvanced Solid TumorEpithelial Ovarian CancerCastration-Resistant Prostatic CancerHepatocellular Cancer
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 278
- Registration Number
- NCT05293496
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Florida Cancer Specialists and Research Institute, Sarasota, Florida, United States
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
- Conditions
- Human Immunodeficiency Virus Type 1Immunodeficiency Virus Type 1, HumanHuman Immunodeficiency Virus I Infection
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 17
- Registration Number
- NCT05261191
- Locations
- 🇺🇸
Icahn School of Medicine at Mt. Sinai, New York, New York, United States
🇺🇸UNC Hospital - Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸Case Western Reserve University Hospital, Cleveland, Ohio, United States
Flotetuzumab Expanded Access Program
- Conditions
- Acute Myeloid LeukemiaAMLAML, Adult Recurrent
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- MacroGenics
- Registration Number
- NCT04678466
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
- Conditions
- Head and Neck Squamous Cell CarcinomaHead and Neck NeoplasmsHead and Neck Cancer
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 62
- Registration Number
- NCT04634825
- Locations
- 🇺🇸
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States